Navigation Links
Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
Date:2/16/2011

RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally available antiviral therapeutics, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of Chimerix's broad spectrum antiviral drug candidate, CMX001, as a medical countermeasure in the event of a smallpox release.

CMX001 is a potential dual-use therapeutic with evidence of antiviral activity against all five families of double-stranded DNA (dsDNA) viruses that cause morbidity and mortality in humans, including smallpox.  Under the terms of the BARDA contract, Chimerix will receive committed funding of $24.8 million during the first year with subsequent option periods that, if completed, would bring the total contract value to $81.1 million.  

The funding from BARDA builds upon the $37 million Chimerix previously received from the National Institute of Allergy and Infectious Diseases (NIAID) for development of CMX001 for smallpox, in addition to substantial private investment from top-tier venture capital firms for the development of CMX001 as a treatment for other life-threatening infections such as adenovirus and cytomegalovirus.

As part of progressing the clinical and non-clinical development of CMX001 for the smallpox indication, the BARDA contract will also support expanded human safety trials and the recently initiated CMX001-350 multicenter, open-label clinical study of CMX001 for the treatment of twelve life-threatening or serious conditions caused by dsDNA viruses.  This represents Chimerix's first contract with BARDA and will position CMX001 for possible procurement as a medical countermeasure for the Strategic National Stockpile.

"The activities undertaken as part of the BARDA contract will provide significant value to Chimerix's overall development program for CMX001 for the prophylaxis, preempti
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
2. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
3. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
4. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
5. Chimerix to Present at Upcoming Investor Conferences
6. Chimerix Initiates Phase 1 Study of CMX157
7. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
8. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
9. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
10. Chimerix Joins International Network of Organizations to Cure Malaria
11. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 zFlo Motion , ... to announce an exciting product from a new partner. ... solutions over the past 15 years, with offerings in the ... their 3D IMU system (inertial measurement unit), iSen, is opening ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Md. , and INDIANAPOLIS , Feb. 10 ... Corporation (Nasdaq: UTHR ), announced today that it has ... development of ImmuneWorks, lead compound, IW001, a purified bovine Type ... Fibrosis (IPF) and Primary Graft Dysfunction (PGD) in patients receiving ...
... Early ... ... 10, 2010 -- Companies in the Life Sciences sector, which includes the biotechnology and ... the relative strength of the sector during the economic downturn, according to PricewaterhouseCoopers LLP ...
... , , - Additional AeroLEF patents granted in ... , MISSISSAUGA, ON , Feb. 10 /PRNewswire-FirstCall/ ... it has been granted two additional patents in the US ... liposome-encapsulated fentanyl in development for the treatment of moderate to ...
Cached Biology Technology:Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 3Life Sciences Venture Capital Funding Overcomes Record Lows, Outpaces Other Sectors, According to PricewaterhouseCoopers 2Life Sciences Venture Capital Funding Overcomes Record Lows, Outpaces Other Sectors, According to PricewaterhouseCoopers 3Life Sciences Venture Capital Funding Overcomes Record Lows, Outpaces Other Sectors, According to PricewaterhouseCoopers 4YM BioSciences granted two US patents for AeroLEF(R) 2YM BioSciences granted two US patents for AeroLEF(R) 3YM BioSciences granted two US patents for AeroLEF(R) 4
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Monitor: North America Perimeter Security Systems Market" report to ... The North American perimeter security market is estimated to ... Although the U.S. market holds a larger share in this ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Scientists have shown for the first time that carbon nanotubes ... The new technique could change the way doctors treat broken ... into a fracture to promote healing. , The report appears ... journal Chemistry of Materials. ACS is the world's largest scientific ...
... you burned your finger on a hot stove? Imagine what ... or feet all the time and know there's virtually nothing ... neuropathic pain, and it's a common complication of many diseases ... this type of pain, which is caused by damage to ...
... Diego biochemists have developed a computer program that helps ... play different roles in a wide range of cellular ... , Prior to the UCSD team's findings, which ... journal Science, many scientists expressed doubts that a computational ...
Cached Biology News:Nanotubes inspire new technique for healing broken bones 2Nanotubes inspire new technique for healing broken bones 3Scientists use gene transfer technology and common virus to block neuropathic pain in animals 2Scientists use gene transfer technology and common virus to block neuropathic pain in animals 3Scientists use gene transfer technology and common virus to block neuropathic pain in animals 4Scientists use gene transfer technology and common virus to block neuropathic pain in animals 5Computer modeling reveals hidden conversations within cells 2Computer modeling reveals hidden conversations within cells 3
... within neurons in vesicles called synaptosomes. ... synaptic bouton. Synaptosomes may be ... other cellular debris. Abnormalites in neurotransmitter ... pathological condtions. Conditions of release ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,515-8) ...
... value of your microarray data using ... support you need from consultation to ... up to date methods. Utilize our ... Expression Profiling Service or from your ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,518-2) ... assistance. Material: cap polystyrene ...
Biology Products: